申请人:Linx Pharmaceutical Co., Ltd.
公开号:EP2924037A1
公开(公告)日:2015-09-30
The present invention relates to the new use and target of a compound of formula I such as terazosin. In particular, the present invention relates to the use of the compound of formula I in the preparation of drugs used as an apoptosis inhibitor or drugs for treating and/or preventing sepsis and the complications thereof. The present invention provides a new method and direction for inhibiting apoptosis and treating and/or preventing sepsis and the complications thereof.
本发明涉及特拉唑嗪等式 I 化合物的新用途和目标。特别是,本发明涉及式 I 化合物在制备用作细胞凋亡抑制剂的药物或治疗和/或预防败血症及其并发症的药物中的用途。本发明为抑制细胞凋亡、治疗和/或预防败血症及其并发症提供了一种新的方法和方向。